Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision.

29 Oct 2021

Beckman Coulter Life Sciences expands customer access to experts, resources with 3D Digital Campus

Building on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus.

From Beckman Coulter Life Sciences - Flow Cytometry 29 Oct 2021

Breakthrough COVID infections in Northeast Italy showing waning vaccine protection

Researchers analyze an outbreak of breakthrough infections in a small nursing home in Northerneastern Italy.

28 Oct 2021

How long does natural or vaccine-induced immunity to COVID last?

Researchers present a comprehensive assessment on SARS-CoV-2 induced immunity.

28 Oct 2021

Importance of boosters after priming with J&J Ad26.COV2.S COVID-19 vaccine

A new study compares healthcare workers who underwent homologous Ad26.COV2.S booster vaccination to those who underwent heterologous boosting.

28 Oct 2021

Third dose of Covid-19 vaccine benefits dialysis patients

In some patients, the immune system responds poorly to the second vaccination dose. This changes with the third shot.

28 Oct 2021

Study offers hope for a new therapeutic option for patients with severe asthma

A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Medicine.

28 Oct 2021

Study suggests third dose of the Pfizer vaccine could reduce SARS-CoV-2 transmission

A new study examined protection against symptomatic coronavirus disease 2019 (COVID-19) from non-Delta variants using data from randomized control trials.

28 Oct 2021

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Researchers investigated the neutralizing antibody response that different mRNA vaccines induce in both previously convalescent and SARS-CoV-2 naïve individuals.

28 Oct 2021

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

In this study, a team of researchers from Japanese institutions provide a panel of broadly neutralizing nanobodies that detect four VOCs.

28 Oct 2021

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Sphere Fluidics announced today that it has closed a $40 million (circa £30 million) investment round.

From Fluidic Sciences and Sphere Bio 28 Oct 2021

Japanese study on SARS-CoV-2 breakthrough infections

Researchers evaluated SARS-CoV-2 incidence in Japan regarding the timing of the vaccination program and surge in COVID-19 cases among the staff of a large referral hospital in Tokyo. This study is posted to the medRxiv* preprint server.

28 Oct 2021

N antibodies following SARS-CoV-2 Alpha and Delta infections by vaccination status

A new study, published on the medRxiv* preprint server, has focused on the use of anti-nucleocapsid (N) antibody positivity as a marker of SARS-CoV-2 infection. In the present study, these antibody markers were evaluated using serological surveillance studies post-vaccination amidst circulation of variants of concern.

28 Oct 2021

Routine surveillance helps detect asymptomatic SARS-CoV-2 vaccine breakthrough infections

In a study published in Annals of Internal Medicine, researchers from Italy systematically monitored 2,397 HCWs who were fully vaccinated with BNT162 at the ASST Settelaghi hospitals in Lombardy, Italy during February 2021. HCWs who worked in 8 wards deemed at “high risk” for infection from attending patients had to undergo mandatory nasopharyngeal swab testing with SARS-CoV-2 polymerase chain reaction every two weeks. HCWs working in 8 “moderate-risk” wards were tested every four weeks.

28 Oct 2021

Antibody News and Research

Further Reading

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

Beckman Coulter Life Sciences expands customer access to experts, resources with 3D Digital Campus

Breakthrough COVID infections in Northeast Italy showing waning vaccine protection

How long does natural or vaccine-induced immunity to COVID last?

Importance of boosters after priming with J&J Ad26.COV2.S COVID-19 vaccine

Third dose of Covid-19 vaccine benefits dialysis patients

Study offers hope for a new therapeutic option for patients with severe asthma

Study suggests third dose of the Pfizer vaccine could reduce SARS-CoV-2 transmission

Study finds one mRNA vaccine dose after SARS-CoV-2 infection produces highest neutralizing antibody titers

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Japanese study on SARS-CoV-2 breakthrough infections

N antibodies following SARS-CoV-2 Alpha and Delta infections by vaccination status

Routine surveillance helps detect asymptomatic SARS-CoV-2 vaccine breakthrough infections

COVID-19 and subacute neuropsychiatric symptoms in adolescents

Study shows efficacy of a heterologous vaccine regimen to induce mucosal protection against COVID-19

A study on the SARS-CoV-2 B.1.620 lineage

Researchers use a mathematical model to better understand the immune response to vaccines

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination amongst healthcare workers

Event guide: Targeted Therapies Partnering & Licensing Summit Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo